With over 20,000 readers, Contract Pharma is a monthly print and digital magazine focused on the pharmaceutical and biopharmaceutical industries. It specifically covers the evolution of the outsourcing industry, including regulatory changes and new business models.
George I’ons, Head of Product Strategy and Insights, discusses current opportunities for biosimilar manufacturers in the latest edition of Contract Pharma.
He examines key factors that could influence decisions to switch injectable combination products, whether positively or negatively. These factors include confidence in biosimilar products, trust in associated drug delivery devices, safety and regulations, evidence from human factors studies, and finally, proven manufacturing and durability. Read the full article for more details.